Gram-Positive Bacterial Infections
Information
- Disease name
- Gram-Positive Bacterial Infections
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04911270 | Active, not recruiting | N/A | Clinical Decision Support Tool for Vancomycin Dosing in Children | May 9, 2022 | October 2024 |
| NCT03896685 | Active, not recruiting | Phase 3 | Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q) | April 6, 2020 | November 2024 |
| NCT00035269 | Completed | Phase 3 | New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia) | December 2001 | May 2003 |
| NCT00062647 | Completed | Phase 2 | Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia | August 2003 | August 2006 |
| NCT00079976 | Completed | Phase 3 | Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA) | October 2003 | June 2005 |
| NCT00081744 | Completed | Phase 3 | Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects | November 2002 | August 2004 |
| NCT00136292 | Completed | Phase 1 | Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics | August 24, 2005 | August 9, 2006 |
| NCT00147511 | Completed | Phase 4 | Time To Efficacy and Onset Of Action Of Linezolid | June 2003 | June 2005 |
| NCT00167960 | Completed | Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit | January 2005 | ||
| NCT00167999 | Completed | Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units | February 2005 | ||
| NCT03964493 | Completed | Phase 2 | TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection | April 20, 2019 | September 28, 2020 |
| NCT00406198 | Completed | Phase 4 | Impact of Continuous Venovenous Haemofiltration on Organ Failure During the Early Phase of Severe Sepsis | March 1997 | December 1999 |
| NCT00501150 | Completed | N/A | Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections | September 2005 | June 2007 |
| NCT00736554 | Completed | What is the Prevalence of Methicillin-Resistant Staphylococcus Aureus in Skin and Soft Tissue Infections Presenting to the Emergency Departments of a Canadian Academic Health Care Center? | July 2008 | November 2008 | |
| NCT03747497 | Completed | Phase 2 | Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection | November 15, 2018 | March 26, 2019 |
| NCT00874367 | Completed | Early-Onset Sepsis Surveillance Study | February 2006 | May 2011 | |
| NCT03560440 | Completed | Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients | June 2014 | June 2017 | |
| NCT01412801 | Completed | Phase 2 | Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings | September 2011 | December 2012 |
| NCT01564758 | Completed | Post Marketing Surveillance Study on Linezolid | February 2004 | March 2005 | |
| NCT03361163 | Completed | Phase 1 | Controlled Human Infection for Vaccination Against Streptococcus Pyogenes | July 10, 2018 | April 21, 2020 |
| NCT03159403 | Completed | A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting | April 12, 2017 | March 8, 2018 | |
| NCT02750761 | Completed | Phase 1 | A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013) | May 2, 2016 | December 21, 2018 |
| NCT00037050 | Completed | Phase 3 | Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria | April 2002 | July 2005 |
| NCT06444802 | Not yet recruiting | Phase 3 | Model-informed Precision Dosing for Linezolid | September 1, 2024 | June 30, 2026 |
| NCT05824988 | Recruiting | Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease | April 14, 2023 | October 2026 | |
| NCT02013141 | Terminated | Phase 4 | Telavancin Pediatric PK Study (Ages >3 Months to 17 Years) | December 2014 | March 2021 |
| NCT00240747 | Terminated | Phase 3 | Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients | June 2000 | January 2005 |
| NCT04847921 | Terminated | Phase 2/Phase 3 | Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition | April 30, 2021 | October 5, 2023 |
| NCT00108433 | Terminated | Phase 3 | Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections | September 2005 | September 2006 |
| NCT00055198 | Terminated | Phase 3 | Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria | December 19, 2002 | January 26, 2004 |
| NCT00835783 | Terminated | Validation Study of Combined Positron Emission Tomography/Computer Tomography to Diagnose Infection and Inflammation | November 2008 | December 2013 | |
| NCT00529282 | Terminated | Phase 3 | A Study of Ceftobiprole in Patients With Fever and Neutropenia. | October 2007 | January 2008 |
| NCT01212432 | Unknown status | Phase 2 | Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study | December 2009 | March 2010 |
| NCT04917380 | Unknown status | The Clinical Character，Risk and Prognosis of Post-neurosurgical Intracranial Infection With Different Pathogens. | June 10, 2021 | October 30, 2021 | |
| NCT03438214 | Unknown status | Phase 4 | Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients | April 28, 2018 | December 1, 2022 |
| NCT03982030 | Withdrawn | Phase 4 | Dalbavancin Outpatient Pilot | April 2023 | July 2025 |
- MedGen concept unique identifier (MedGen Concept name)
- C0085426
- MedGen unique identifier (MedGen Concept name)
- 39283
- MeSH unique ID (MeSH (Medical Subject Headings))
- D016908